GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BrightPath Biotherapeutics Co Ltd (TSE:4594) » Definitions » Price-to-Owner-Earnings

BrightPath Biotherapeutics Co (TSE:4594) Price-to-Owner-Earnings : (As of May. 10, 2024)


View and export this data going back to 2015. Start your Free Trial

What is BrightPath Biotherapeutics Co Price-to-Owner-Earnings?

As of today (2024-05-10), BrightPath Biotherapeutics Co's share price is 円58.00. BrightPath Biotherapeutics Co does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for BrightPath Biotherapeutics Co's Price-to-Owner-Earnings or its related term are showing as below:


TSE:4594's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.99
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-10), BrightPath Biotherapeutics Co's share price is 円58.00. BrightPath Biotherapeutics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円-19.28. Therefore, BrightPath Biotherapeutics Co's PE Ratio for today is At Loss.

As of today (2024-05-10), BrightPath Biotherapeutics Co's share price is 円58.00. BrightPath Biotherapeutics Co's EPS without NRI for the trailing twelve months (TTM) ended in was 円-19.10. Therefore, BrightPath Biotherapeutics Co's PE Ratio without NRI for today is At Loss.

During the past 9 years, BrightPath Biotherapeutics Co's highest PE Ratio without NRI was 1.63. The lowest was 0.00. And the median was 1.46.


BrightPath Biotherapeutics Co Price-to-Owner-Earnings Historical Data

The historical data trend for BrightPath Biotherapeutics Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrightPath Biotherapeutics Co Price-to-Owner-Earnings Chart

BrightPath Biotherapeutics Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - - - - -

BrightPath Biotherapeutics Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BrightPath Biotherapeutics Co's Price-to-Owner-Earnings

For the Biotechnology subindustry, BrightPath Biotherapeutics Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrightPath Biotherapeutics Co's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where BrightPath Biotherapeutics Co's Price-to-Owner-Earnings falls into.



BrightPath Biotherapeutics Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

BrightPath Biotherapeutics Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=58.00/-25.48
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BrightPath Biotherapeutics Co  (TSE:4594) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


BrightPath Biotherapeutics Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of BrightPath Biotherapeutics Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


BrightPath Biotherapeutics Co (TSE:4594) Business Description

Traded in Other Exchanges
N/A
Address
2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.

BrightPath Biotherapeutics Co (TSE:4594) Headlines

No Headlines